CDKN2B-AS1 and neoplasm: ANRIL can also drive tumor progression by regulating various pathways including the mTOR, MAPK, PI3K/AKT, and TGF-β(Yu et al. 2018; Wang et al. 2022a, b; Liu et al. 2019; Dong et al. 2018).